Filtered By:
Drug: Temodar

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 98 results found since Jan 2013.

Rt-40 * the down-regulation of h-ferritin as an adjuvant therapy in human glioma
This study supports the potential of H-ferritin siRNA as an adjuvant therapy in glioma treatment.
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Pang, M., Liu, X., Madhankumar, A. B., Slagle-Webb, B., Connor, J. Tags: RADIATION THERAPY (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research

MutL homolog 1 contributes to temozolomide-induced autophagy via ataxia-telangiectasia mutated in glioma.
Abstract In the present study, mutL homolog 1 (MLH1) small interfering (si)RNA, KU‑55933, an ataxia‑telangiectasia mutated (ATM) inhibitor, and compound C, an adenosine monophosphate‑activated protein kinase (AMPK) inhibitor, were used to investigate the mechanisms underlying temozolomide (TMZ)‑induced autophagy and to determine the role of MLH1 and ATM in autophagy. MLH1 siRNA and KU‑55933 inhibited the phosphorylation of AMPK and ULK1 and reduced the levels of autophagy. MLH1 siRNA inhibited the phosphorylation of ATM and attenuated TMZ cytotoxicity, whereas the inhibition of ATM‑AMPK augmented TM...
Source: Molecular Medicine - February 3, 2015 Category: Molecular Biology Authors: Zou Y, Wang Q, Wang W Tags: Mol Med Rep Source Type: research

Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1
In conclusion, our study demonstrated that hSNF2H was overexpressed in human gliomas and contributed to glioma proliferation, invasion, and chemoresistance through regulation of cyclin E and NF-κB pathway, which is dependent on its interaction with Rsf-1.
Source: Tumor Biology - December 14, 2015 Category: Cancer & Oncology Source Type: research

Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells
Conclusion: In addition to the DNA damage it does, its inhibitory effect on IKCa channels accompanied by membrane depolarization could be an important mechanism underlying TMZ-induced antineoplastic actions.Cell Physiol Biochem 2016;38:1727-1742
Source: Cellular Physiology and Biochemistry - May 9, 2016 Category: Cytology Source Type: research

Frequent Nek1 overexpression in human gliomas.
Abstract Never in mitosis A (NIMA)-related kinase 1 (Nek1) regulates cell cycle progression to mitosis. Its expression and potential functions in human gliomas have not been studied. Here, our immunohistochemistry (IHC) assay and Western blot assay results showed that Nek1 expression was significantly upregulated in fresh and paraffin-embedded human glioma tissues. Its level in normal brain tissues was low. Nek1 overexpression in human gliomas was correlated with the proliferation marker (Ki-67), tumor grade, Karnofsky performance scale (KPS) and more importantly, patients' poor survival. Further studies showed th...
Source: Biochemical and Biophysical Research communications - May 28, 2016 Category: Biochemistry Authors: Zhu J, Cai Y, Liu P, Zhao W Tags: Biochem Biophys Res Commun Source Type: research

G protein-coupled receptor kinase 6 is overexpressed in glioma and promotes glioma cell proliferation.
Authors: Xu LQ, Tan SB, Huang S, Ding HY, Li WG, Zhang Y, Li SQ, Wang T Abstract The expression and potential biological functions of G protein-coupled receptor kinase 6 (GRK6) in human glioma are tested in this study. We show that protein and mRNA expression of GRK6 in human glioma tissues was significantly higher than that in the normal brain tissues. Further immunohistochemistry assay analyzing total 118 human glioma tissues showed that GRK6 over-expression was correlated with glioma pathologic grade and patients' Karnofsky performance status (KPS) score. At the molecular level, in the GRK6-low H4 glioma cells, ...
Source: Oncotarget - May 10, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells
ConclusionsFrom our data we conclude that the mechanisms underlying hypoxia-induced CD133-mediated cisplatin resistance may be instrumental for the design of new GBM treatment strategies.
Source: Cellular Oncology - February 28, 2018 Category: Cancer & Oncology Source Type: research

Tim-3 expression in glioma cells is associated with drug resistance
Conclusions: The presence of Tim-3 mRNA and protein in glioma cells was detected. Significantly, knocking down Tim-3 expression improved the potential of TMZ treatment.
Source: Journal of Cancer Research and Therapeutics - August 13, 2019 Category: Cancer & Oncology Authors: Ji Zhang Zheng Quan Zhu Yan Xia Li Qiu Feng Zhuang Yuanhong Lai Shao Fang Li Xiao Bing Xu Jian Min Liu Source Type: research

Micro-RNA29b Enhances the Sensitivity of GlioblastomaMultiforme Cells to Temozolomide by Promoting Autophagy.
CONCLUSION: miR-29b potentiates TMZ sensitivity against GBM cells by inducing autophagy and the combined use of miR-29 mimic and TMZ might represent a potential therapeutic strategy for GBM patients. This article is protected by copyright. All rights reserved. PMID: 32275350 [PubMed - as supplied by publisher]
Source: Anatomical Record - April 9, 2020 Category: Anatomy Authors: Xu JX, Yang Y, Zhang X, Luan XP Tags: Anat Rec (Hoboken) Source Type: research

The guanine nucleotide exchange factor, LARG, and RhoC play a role in glioblastoma cell invasion and resistance.
Abstract Glioblastoma (GBM) is the most common primary malignant brain cancer in adults. A hallmark of GBM is aggressive invasion of tumor cells into the surrounding normal brain. The current standard of care therapy, as well as targeted therapies, have largely failed to specifically address this issue. Therefore, identifying key regulators of GBM cell migration and invasion is of particular interest. The leukemia-associated RhoGEF (LARG) has previously been implicated in cell invasion in other tumor types; however, the role of LARG in GBM pathobiology remains undefined. Here, we report that the expression level o...
Source: The American Journal of Pathology - July 17, 2020 Category: Pathology Authors: Ding Z, Dong Z, Yang Y, Fortin Ensign SP, Sabit H, Nakada M, Ruggieri R, Kloss JM, Symons M, Tran NL, Loftus JC Tags: Am J Pathol Source Type: research

Silencing of ZFP36L2 increases sensitivity to temozolomide through G2/M cell cycle arrest and BAX mediated apoptosis in GBM cells.
Abstract Despite the advancements in primary brain tumour diagnoses and treatments, the mortality rate remains high, particularly in glioblastoma (GBM). Chemoresistance, predominantly in recurrent cases, results in decreased mean survival of patients with GBM. We aimed to determine the chemosensitisation and oncogenic characteristics of zinc finger protein 36-like 2 (ZFP36L2) in LN18 GBM cells via RNA interference (RNAi) delivery. We conducted a meta-analysis of microarray datasets and RNAi screening using pooled small interference RNA (siRNA) to identify the druggable genes responsive to GBM chemosensitivity. Tem...
Source: Molecular Biology Reports - February 15, 2021 Category: Molecular Biology Authors: Che Mat MF, Mohamad Hanif EA, Abdul Murad NA, Ibrahim K, Harun R, Jamal R Tags: Mol Biol Rep Source Type: research

Cancers, Vol. 13, Pages 944: Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma
wn Spencer J. Collis Brain tumours kill more children and adults under 40 than any other cancer, with approximately half of primary brain tumours being diagnosed as high-grade malignancies known as glioblastomas. Despite de-bulking surgery combined with chemo-/radiotherapy regimens, the mean survival for these patients is only around 15 months, with less than 10% surviving over 5 years. This dismal prognosis highlights the urgent need to develop novel agents to improve the treatment of these tumours. To address this need, we carried out a human kinome siRNA screen to identify potential drug targets that augment the e...
Source: Cancers - February 24, 2021 Category: Cancer & Oncology Authors: Natasha Carmell Ola Rominiyi Katie N. Myers Connor McGarrity-Cottrell Aurelie Vanderlinden Nikita Lad Eva Perroux-David Sherif F. El-Khamisy Malee Fernando Katherine G. Finegan Stephen Brown Spencer J. Collis Tags: Article Source Type: research

TRIM66 Overexpression Promotes Glioma Progression and Regulates Glucose Uptake Through cMyc/GLUT3 Signaling
CONCLUSION: TRIM66 was upregulated in human gliomas, where it promoted cell growth and chemoresistance. Our data also identified novel roles of TRIM66 in glioma progression. TRIM66 upregulates glucose uptake and mitochondrial function through the cMyc/GLUT3 signaling, which makes it a potential therapeutic target.PMID:34234562 | PMC:PMC8256720 | DOI:10.2147/CMAR.S293728
Source: Cell Research - July 8, 2021 Category: Cytology Authors: Yuequn Song Lifang Meng Jian Yu Zhi Cao Jizhou Sun Hongyu Zhao Source Type: research

Temozolomide Drives Ferroptosis via a DMT1-Dependent Pathway in Glioblastoma Cells
CONCLUSION: Taken together, our findings indicate that temozolomide may suppress cell growth partly by inducing ferroptosis by targeting DMT1 expression in glioblastoma cells.PMID:34427071 | DOI:10.3349/ymj.2021.62.9.843
Source: Yonsei Medical Journal - August 24, 2021 Category: Universities & Medical Training Authors: Qingxin Song Shanxin Peng Zhiqing Sun Xueyuan Heng Xiaosong Zhu Source Type: research